Karyopharm Therapeutics submitted a supplemental NDA to the FDA seeking Accelerated Approval for XPOVIO (selinexor) in combination with ruxolitinib for myelofibrosis patients. The company requested Priority Review, which could tighten the FDA timeline if granted. Overall, this is a positive regulatory step that may support investor sentiment for KPTI’s myelofibrosis program.
Karyopharm Therapeutics submitted a supplemental NDA to the FDA seeking Accelerated Approval for XPOVIO (selinexor) in combination with ruxolitinib for myelofibrosis patients. The company requested Priority Review, which could tighten the FDA timeline if granted. Overall, this is a positive regulatory step that may support investor sentiment for KPTI’s myelofibrosis program.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
